Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2021-06-21 Capital/Financing Update
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT - ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acceptance by the Shanghai Stock Exchange of application materials for a proposed issue of A shares by RemeGen Co., Ltd. It references regulatory rules and the submission of a prospectus but does not contain financial statements or detailed financial data. The document is relatively short (3329 characters) and serves as an update on the company's capital raising process rather than a full report. Therefore, it fits the category of a Capital/Financing Update (CAP).
2021-06-21 English
VERY SUBSTANTIAL ACQUISITION ACQUISITION OF LAND USE RIGHTS IN HEFEI AIRPORT INTERNATIONAL TOWN
M&A Activity Classification · 95% confidence The document is an announcement by Overseas Chinese Town (Asia) Holdings Limited regarding a very substantial acquisition of land use rights in Hefei Airport International Town. It details the acquisition terms, consideration, and implications under the Hong Kong Stock Exchange Listing Rules, specifically referencing Chapter 14 which governs substantial acquisitions. The document is an announcement of a transaction (land acquisition) and not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or board change announcement. The content fits the category of M&A Activity as it relates to a significant acquisition transaction by the company. The document length is substantial and contains detailed transaction information, consistent with M&A announcements. Therefore, the appropriate classification is 'TAR' (M&A Activity).
2021-06-17 English
ANNOUNCEMENT REGARDING H SHARE FULL CIRCULATION PROGRESS OF COMPLETION
Capital/Financing Update Classification · 95% confidence The document is an announcement from RemeGen Co., Ltd. regarding the completion of the H share full circulation progress. It references previous announcements and details procedural updates related to share circulation and trading arrangements. The document is relatively short (2511 characters) and does not contain financial statements, detailed financial data, or management discussion. It is an update on a capital market process rather than a full financial report or regulatory certification. The content fits best with a Capital/Financing Update (CAP) as it relates to share circulation and trading rights, which are aspects of capital structure and financing activities.
2021-06-11 English
EXCHANGE NOTICE - RESUMPTION OF TRADING
Regulatory Filings Classification · 95% confidence The document is a short notice from the Hong Kong Stock Exchange regarding the resumption of trading for a specific company's shares. It does not contain financial statements, management reports, or other detailed disclosures, but rather serves as a regulatory announcement regarding market activity. As it does not fit into specific categories like 'Delisting' or 'Share Issue', it falls under the general regulatory filing category.
2021-06-10 English
INSIDE INFORMATION ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL MARKETING APPROVAL FOR DISITAMAB VEDOTIN TO TREAT LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER (GASTROES
Regulatory Filings Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the conditional marketing approval granted by the National Medical Products Administration for a drug (disitamab vedotin) and the resumption of trading on the Hong Kong Stock Exchange. It is clearly labeled as an "INSIDE INFORMATION ANNOUNCEMENT" and includes regulatory references such as Rule 13.09(2)(a) of the Listing Rules and the Securities and Futures Ordinance. The content focuses on a regulatory approval event and trading resumption, not on financial results, management changes, or detailed financial data. The document length is 4309 characters, which is relatively short and typical for an announcement rather than a full report. There is no financial data or detailed report content, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a Board/Management change announcement, nor a voting result or dividend notice. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about a material event affecting the company’s securities and operations but does not fit other specific categories.
2021-06-09 English
ANNOUNCEMENT - TRADING HALT
Regulatory Filings Classification · 95% confidence The document is an announcement from RemeGen Co., Ltd. regarding a trading halt on its shares on the Hong Kong Stock Exchange. It states that trading has been halted pending the release of a further announcement related to inside information. The document is short (1451 characters) and does not contain any financial data, report content, or detailed disclosures. It is clearly an announcement about a trading halt, which is a regulatory announcement related to market trading status rather than a financial report or other specific filing type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2021-06-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.